About the journal
Frontiers in Drug Discovery is an open-access journal published by Frontiers Media S.A. in Switzerland, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 1,950 CHF. Declared review time at DOAJ: 15 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Frontiers Media S.A.
- ISSN
- 2674-0338
- Country
- Switzerland
- Languages
- english
- Access
- Open access
- Declared publication charge
- 1,950 CHF
- Articles in DOAJ
- 147
- Declared review time
- 15 weeks
- Declared peer-review model
- peer_review
- Official website
- https://www.frontiersin.org/journals/drug-discovery
Index listings
- DOAJ · 2022-11-22
- Indexing
- DOAJ
- APC
- 1,950 CHF
- Declared review time (DOAJ)
- 15 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
147
Most recent article
last month
Average review time (journal-declared via DOAJ)
15weeks
Works in OpenAlex
190
Last recorded publication year
2026
h-index
18
i10-index
43
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2025-05-13
- Added to DOAJ
- 2022-11-22
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSS
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSS
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 93%
- ORCID iDs in current deposits
- 0%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9918350785506676
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Computational Drug Discovery Methods
- Computational Drug Discovery Methods
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 and COVID-19 Research
- vaccines and immunoinformatics approaches
- vaccines and immunoinformatics approaches
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
Show all subjects (50)
- Microbial Natural Products and Biosynthesis
- Microbial Natural Products and Biosynthesis
- Machine Learning in Materials Science
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- Malaria Research and Control
- COVID-19 Clinical Research Studies
- COVID-19 Clinical Research Studies
- Machine Learning in Materials Science
- Malaria Research and Control
- Machine Learning in Bioinformatics
- Biosimilars and Bioanalytical Methods
- Genetics, Bioinformatics, and Biomedical Research
- Machine Learning in Bioinformatics
- Trypanosoma species research and implications
- Biosimilars and Bioanalytical Methods
- Pharmacogenetics and Drug Metabolism
- Pharmacogenetics and Drug Metabolism
- Genetics, Bioinformatics, and Biomedical Research
- Trypanosoma species research and implications
- Treatment of Major Depression
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Protein Structure and Dynamics
- Ubiquitin and proteasome pathways
- Metabolomics and Mass Spectrometry Studies
- Mosquito-borne diseases and control
- Treatment of Major Depression
- Metabolomics and Mass Spectrometry Studies
- Protein Structure and Dynamics
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Mosquito-borne diseases and control
- Antimicrobial Peptides and Activities
- Ubiquitin and proteasome pathways
- Psoriasis: Treatment and Pathogenesis
- Epigenetics and DNA Methylation
- Psoriasis: Treatment and Pathogenesis
- Heart Failure Treatment and Management
- Epigenetics and DNA Methylation
- Heart Failure Treatment and Management
- HIV/AIDS drug development and treatment
Keywords (DOAJ)
- pharmacology
- basic pharmacology
- bioinformatics
- cheminformatics
- cardiology
- clinical pharmacology
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ